Toxins from Animal Venoms As a Potential Source of Antimalarials: A Comprehensive Review

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2023 Jun 27

PMID 37368676

Authors

Zeca M Salimo

Andre L Barros

Asenate A X Adriao

Aline M Rodrigues

Marco A Sartim

Isadora S de Oliveira

Manuela B Pucca

Djane C Baia-da-Silva

Wuelton M Monteiro

Gisely C de Melo

Hector H F Koolen

Affiliations

Soon will be listed here.

Abstract

Malaria is an infectious disease caused by spp. and it is mainly transmitted to humans by female mosquitoes of the genus . Malaria is an important global public health problem due to its high rates of morbidity and mortality. At present, drug therapies and vector control with insecticides are respectively the most commonly used methods for the treatment and control of malaria. However, several studies have shown the resistance of to drugs that are recommended for the treatment of malaria. In view of this, it is necessary to carry out studies to discover new antimalarial molecules as lead compounds for the development of new medicines. In this sense, in the last few decades, animal venoms have attracted attention as a potential source for new antimalarial molecules. Therefore, the aim of this review was to summarize animal venom toxins with antimalarial activity found in the literature. From this research, 50 isolated substances, 4 venom fractions and 7 venom extracts from animals such as anurans, spiders, scorpions, snakes, and bees were identified. These toxins act as inhibitors at different key points in the biological cycle of and may be important in the context of the resistance of to currently available antimalarial drugs.

Citing Articles

Antischistosomal Potential of Animal-Derived Natural Products and Compounds.

Fischer-Carvalho A, Taveira-Barbosa T, Verjovski-Almeida S, Haeberlein S, Sena Amaral M Microorganisms. 2025; 13(2).

PMID: 40005763 PMC: 11858059. DOI: 10.3390/microorganisms13020397.

Exploiting venom toxins in paratransgenesis to prevent mosquito-borne disease.

French S, Da Silva R, Storm J, Wastika C, Cullen I, Have M Parasit Vectors. 2025; 18(1):32.

PMID: 39881388 PMC: 11776213. DOI: 10.1186/s13071-025-06663-9.

Antimalarial efficacy of skin extract via inhibition of Na/H ATPase.

Bagwe A, DSouza R, Sharma B J Parasit Dis. 2024; 48(4):831-848.

PMID: 39493482 PMC: 11527857. DOI: 10.1007/s12639-024-01716-9.

References

Kayano A, Simoes-Silva R, Medeiros P, Maltarollo V, Honorio K, Oliveira E . BbMP-1, a new metalloproteinase isolated from Bothrops brazili snake venom with in vitro antiplasmodial properties. Toxicon. 2015; 106:30-41. DOI: 10.1016/j.toxicon.2015.09.005. View

Ghosh A, Edwards M, Jacobs-Lorena M . The journey of the malaria parasite in the mosquito: hopes for the new century. Parasitol Today. 2000; 16(5):196-201. DOI: 10.1016/s0169-4758(99)01626-9. View

Guillaume C, Calzada C, Lagarde M, Schrevel J, Deregnaucourt C . Interplay between lipoproteins and bee venom phospholipase A2 in relation to their anti-Plasmodium toxicity. J Lipid Res. 2006; 47(7):1493-506. DOI: 10.1194/jlr.M600111-JLR200. View

Kerschbaumer G, Wernsdorfer G, Wiedermann U, Congpuong K, Sirichaisinthop J, Wernsdorfer W . Synergism between mefloquine and artemisinin and its enhancement by retinol in Plasmodium falciparum in vitro. Wien Klin Wochenschr. 2010; 122 Suppl 3:57-60. DOI: 10.1007/s00508-010-1439-5. View

Rodrigues F, Santos M, de Carvalho T, Rocha B, Riehle M, Pimenta P . Expression of a mutated phospholipase A2 in transgenic Aedes fluviatilis mosquitoes impacts Plasmodium gallinaceum development. Insect Mol Biol. 2008; 17(2):175-83. PMC: 4137777. DOI: 10.1111/j.1365-2583.2008.00791.x. View

Phillips M, Burrows J, Manyando C, Hooft van Huijsduijnen R, Van Voorhis W, Wells T . Malaria. Nat Rev Dis Primers. 2017; 3:17050. DOI: 10.1038/nrdp.2017.50. View

Tadesse F, Ashine T, Teka H, Esayas E, Messenger L, Chali W . Anopheles stephensi Mosquitoes as Vectors of Plasmodium vivax and falciparum, Horn of Africa, 2019. Emerg Infect Dis. 2021; 27(2):603-607. PMC: 7853561. DOI: 10.3201/eid2702.200019. View

Yavo W, Bla K, Djaman A, Assi S, Basco L, MAZABRAUD A . In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire). Afr Health Sci. 2011; 10(2):111-6. PMC: 2956299. View

Deregnaucourt C, Schrevel J . Bee venom phospholipase A2 induces stage-specific growth arrest of the intraerythrocytic Plasmodium falciparum via modifications of human serum components. J Biol Chem. 2000; 275(51):39973-80. DOI: 10.1074/jbc.M006712200. View

10.

Silva-Pinto A, Domingos J, Cardoso M, Reis A, Diez Benavente E, Caldas J . Artemether-lumefantrine treatment failure of uncomplicated Plasmodium falciparum malaria in travellers coming from Angola and Mozambique. Int J Infect Dis. 2021; 110:151-154. PMC: 8461077. DOI: 10.1016/j.ijid.2021.07.008. View

11.

Bastianelli G, Bouillon A, Nguyen C, Crublet E, Petres S, Gorgette O . Computational reverse-engineering of a spider-venom derived peptide active against Plasmodium falciparum SUB1. PLoS One. 2011; 6(7):e21812. PMC: 3144881. DOI: 10.1371/journal.pone.0021812. View

12.

Bava R, Castagna F, Musella V, Lupia C, Palma E, Britti D . Therapeutic Use of Bee Venom and Potential Applications in Veterinary Medicine. Vet Sci. 2023; 10(2). PMC: 9965945. DOI: 10.3390/vetsci10020119. View

13.

Sinden R . A cell biologist's view of host cell recognition and invasion by malarial parasites. Trans R Soc Trop Med Hyg. 1985; 79(5):598-605. DOI: 10.1016/0035-9203(85)90165-8. View

14.

Favuzza P, Guffart E, Tamborrini M, Scherer B, Dreyer A, Rufer A . Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. Elife. 2017; 6. PMC: 5349852. DOI: 10.7554/eLife.20383. View

15.

Fang Y, He X, Zhang P, Shen C, Mwangi J, Xu C . In Vitro and In Vivo Antimalarial Activity of LZ1, a Peptide Derived from Snake Cathelicidin. Toxins (Basel). 2019; 11(7). PMC: 6669622. DOI: 10.3390/toxins11070379. View

16.

Noronha E, Alecrim M, Romero G, Macedo V . [RIII mefloquine resistance in children with falciparum malaria in Manaus, AM, Brazil]. Rev Soc Bras Med Trop. 2000; 33(2):201-5. View

17.

Alecrim M das G, Alecrim W, Macedo V . Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev Soc Bras Med Trop. 1999; 32(1):67-8. DOI: 10.1590/s0037-86821999000100013. View

18.

Parthasarathy S, Steinbrecher U, Barnett J, Witztum J, Steinberg D . Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1985; 82(9):3000-4. PMC: 397694. DOI: 10.1073/pnas.82.9.3000. View

19.

Price R, Marfurt J, Chalfein F, Kenangalem E, Piera K, Tjitra E . In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother. 2010; 54(12):5146-50. PMC: 2981240. DOI: 10.1128/AAC.00801-10. View

20.

Marfurt J, Wirjanata G, Prayoga P, Chalfein F, Leonardo L, Sebayang B . Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. Int J Parasitol Drugs Drug Resist. 2021; 17:46-56. PMC: 8358472. DOI: 10.1016/j.ijpddr.2021.06.002. View